Pfizer’s oral antiviral drug was found to reduce the risk of hospitalization or death from COVID-19 by 89%, according to interim results from a mid-to-late-stage study announced by the company on Friday. From a report: Antiviral drugs can be a key pandemic-fighting tool, as not everyone will get vaccinated against the virus and it may take years to fully inoculate people in certain countries — particularly given current gaps in global vaccine supplies. Pfizer CEO Albert Bourla said in a statement that these findings from the phase 2/3 study marked “a real game-changer in the global efforts to halt the devastation of this pandemic.” Pfizer’s antiviral pill, PAXLOVID (PF-07321332), was developed specifically to treat COVID-19, by blocking activity of the main enzyme the virus needs to multiply. This was co-administered with a low dose of ritonavir, which is widely used in combination treatments for HIV infection.

Read more of this story at Slashdot.

Source: Slashdot – Pfizer Says COVID Pill Cuts Risk of Death or Hospitalization by 89%, Citing Interim Results